On 10 June 2010, Indian-based generics manufacturer, Orchid Chemicals & Pharmaceuticals (Orchid) announced that it had entered into an agreement to acquire Karalex Pharma, LLC, a US-based generic marketing and sales services company with headquarters in New Jersey, USA.
Orchid acquires US generic sales and marketing company Karalex
Home/Pharma News
|
Posted 25/06/2010
0
Post your comment

Through this acquisition, Orchid intends to increase its presence in the US market and to market its generic products directly to US customers.
Karalex Pharma is a leading provider of generic pharmaceuticals focused exclusively on the US healthcare market. Karalex Pharma, LLC, was launched in 2007 as a pharmaceutical company committed to becoming a leading provider of marketing and sales services to US classes of trade for developers and manufacturers of generic pharmaceuticals. Karalex Pharma has launched over 100 generic pharmaceutical products in the US with a combined value in excess of US$1 billion.
Mr K Raghavendra Rao, Managing Director, Orchid Chemicals & Pharmaceuticals said “we are happy that we have established our presence in the generic sales and marketing area with this acquisition. This acquisition will provide a strong commercial US-based sales capability to Orchid”.
The move is expected to pave the way for Orchid’s upcoming generic pharmaceuticals pipeline. It also means that Orchid, for the first time, has complete coverage of the entire generic pharmaceutical business cycle from product development to product sales.
Reference:
Orchid News Updates, Orchid to acquire US-based marketing company Karalex Pharma, LLC, 10 June 2010
Guidelines
FDA issues guidance on AI use in drug and biologicals regulatory decision making
ICH adopts Good Clinical Practice Guideline for clinical trials
Policies & Legislation
NPRA Malaysia trials new timelines for variation applications
Regulatory evolution and impact of simplified requirements for interchangeable biosimilars in the US
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
Bio-Thera partners with Tabuk in Saudi Arabia and SteinCares in LATAM
Klinge-Teva and MS Pharma agreements for Eylea and Stelara biosimilars in Europe and MENA
Biosimilars thrive as China’s biotech industry gains momentum
Greener Pharmaceuticals: WHO's call for innovative regulatory practices and eco-friendly innovations
Bio-Thera partners with Tabuk in Saudi Arabia and SteinCares in LATAM

Home/Pharma News Posted 18/02/2025
Klinge-Teva and MS Pharma agreements for Eylea and Stelara biosimilars in Europe and MENA

Home/Pharma News Posted 06/02/2025
Greener Pharmaceuticals: WHO's call for innovative regulatory practices and eco-friendly innovations

Home/Pharma News Posted 15/01/2025
The best selling biotechnology drugs of 2008: the next biosimilars targets

Post your comment